Trial partnership: Merck’s well known anti PD-1 already works in about 10 percent of women with ovarian cancer. The biomedical hope hare is that a combination of anti-PD-1 (the PD-1 part: a protein known as programmed cell-death receptor-1) and IMV’s vaccine will increase survival percentages, increase safety levels and perhaps decrease treatment costs for consumers and insurance companies.
Enrollment in the new Merck-IMV trial will take place in coming weeks at Princess Margaret Cancer Treatment Centre.
A well known and published ovarian cancer specialist, Amit Oza, is named as lead investigator.
- Just added — Abitibi Royalties To See Growing Interest For Quebec Portfolio Of Properties (Below)
The race for laboratories offering immunological solutions to cancer is to activate more of the killer T-cells that humans need to battle and bonk cancers. Immunovacine’s DPX-Survivac, essentially peptide antigens in a special delivery package, theoretically guides the body’s immune system to recognize deadly cancer cells and kill those cells, the same cancer cells that anti-PD-1 protects.
* A finely done examination of the Merck partnership and Immunovaccine science is out from Echelon Wealth Partners. Doug Loe, a PhD and MBA, examines how DPX-Survivac could find its way into oncological research conducted for Astra-Zeneca, Bristol-Myers Squibb and Roche Labs. Dr. Loe also discusses a possible data trigger from looming human trial results that combined DPX-Survivac and an Incyte compound: 40 patients autumn 2016. Data from Incyte-IMV will see publication in March 2017. Anything that shows stunted tumor growth that surpasses one in 10 patients in fast-acting advanced ovarian cancer is better than anything already available to treat the disease.
Merck via a Toronto hospital will pay all costs for further combination trials that can last as long as 5 years. Considerable clinical data will surface before the close of 2017. Here is a straight governmental agency description of the planned Phase II human trials for Merck-IMV.
If the IMV-Merck combination halts ovarian (and-or fallopian tube) tumor growth in more than 10 percent of the patients — say 20 percent, we will see further human trials at the Toronto hospital. The trials location when they begin is on University Avenue — Princess Margaret Cancer Centre.
For folks suffering from advanced ovarian cancer, next steps in the event looming Phase II human trials see safe and halted tumor growth will be the measurement of reduction in tumor growth, length of the immunological benefits of the combo, and in a figurative sense, quality of life for these women.
This is the IMV notice of the Merck partnership.
Those looking for good science and humanitarian relief for advanced ovarian cancer sufferers will find some reasons to read the latest from IMV and Merck. IMV notice of the Merck partnership.
Just ahead: what could be fresh drill assays that double the size of likely economic gold from Abitibi Royalties’ royalty-producing Odyssey Zone, adjacent to Agnico-Eagle and Yamana Gold’s Canadian Malartic mine and mill in Quebec. The Odyssey zones are just a tad east of Canada’s largest gold mine and mill’s main open pit.